Opexa Therapeutics
Manufacturing · Texas, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
2635 Technology Forest Blvd, The Woodlan...Phone Number
(281) 272-9331Website
www.opexatherapeutics.comRevenue
<$5 MillionStock Symbol
OPXAIndustry
About Opexa Therapeutics
Opexa Therapeutics, Inc., a biopharmaceutical company, develops personalized immunotherapy to treat multiple sclerosis (MS) and other autoimmune diseases based on its proprietary T-cell technology. The companys lead product candidate is Tcelna, a T-cell immunotherapy for the treatment of patients with secondary progressive MS. It is also developing OPX-212, an autologous T-cell immunotherapy that is in preclinical development to treat neuromyelitis optica. The company was formerly known as PharmaFrontiers Corp. and changed its name to Opexa Therapeutics, Inc. in June 2006. Opexa Therapeutics, Inc. was founded in 2003 and is headquartered in The Woodlands,...Explore more
Opexa Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Compare Similar Companies to Opexa Therapeutics
Compare insights from companies similar to Opexa Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Opexa Therapeutics Tech Stack
A closer look at the technologies used by Opexa Therapeutics
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Opexa Therapeutics
Sign Up For FreeTo access detailed company insights
Opexa Therapeutics, Inc., a biopharmaceutical company, develops personalized immunotherapy to treat multiple sclerosis (MS) and other autoimmune diseases based on its proprietary T-cell technology. The companys lead product candidate is Tcelna, a T-cell immunotherapy for the treatment of patients with secondary progressive MS. It is also developing... Read More
